Medical Science Liaison, Oncology at Bristol-Myers Squibb Pvt. Ltd (2021-11 – Present)
Medical Science Liaison specializing in oncology with multiple tours of duty in clinical science and HEOR roles
- Tour of Duty: Clinical Scientist, Hematology (March 2024) - Phase II A study for Luspatercept in pediatric beta-thalassemia and Phase IV study for Beta-Thalassemia & MDS patients
- Developed Protocol amendments, Literature reviews, and Site/CRA training materials
- Monitored clinical data trends and conducted investigator meetings and newsletters
- Prepared Data review Plan and Protocol Deviation Review Plan
- Participated in DMC data review and steering committee presentations
- Tour of Duty: WW HEOR (RCC Lead) (August to January 2024) - Study Director for multi-country pooled analysis in 1L RCC
- Contributed to CEM adaptation for reimbursement in Peru and 1L RCC SLR with Argentina
- Led regional medical activities for West Zone and Southeast regions
- Developed and maintained relationships with Tier 1-3 Thought Leaders in Oncology
- Executed medical plans for 6 indication launches and 4 new asset insights
- Provided medical leadership guidance to commercial and marketing teams
- Promoted advancement of BMS therapies in new indications including Repotrectinib
- Worked with clinical operations on priority phase 3/4 trials
- Trained and onboarded new MSLs through shadowing and mentorship
- Driven 37+ trainings over 16 indications in oncology over 2.5 years
- Conducted 16 regional CMEs and supported 6 International Speaker Programs and 2 Advisory board meetings
- Supported SEC regulatory meetings and presentations for new indications
- Recognized as 1 of 4 Global MSLs for Veeva NGCI MSL Best Practice for India
- Third Place in Global Poster Presentation for Nivolumab launch in Frontline Gastric Cancer
- Served as Indication champion for NSCLC and cHL
- RWE & HEOR POC for India
- Developed innovative SPIN model for RCC key messages communication
- Cost-Effectiveness model adaptation in NSCLC
Fellowship in Oncotherapeutics at Tata Memorial Centre (2020-09 – 2021-08)
Clinical research fellowship focused on oncology with emphasis on geriatric oncology, pharmacokinetics, and real-world evidence studies
- Selected as 1 of 182 MD and PharmD candidates for the fellowship
- Selected as 1 of 40 global delegates for ACORD protocol development workshop
- Developed study comparing potentially inappropriate medications scale in geriatric cancer patients published in Journal of Geriatric Oncology
- Developed and led RWE study on safety and antibody kinetics of Covishield vaccine in Indian adults
- Developed study protocol on impact of clinical pharmacological interventions in ALL and AML patients
- Developed Phase II CLARITY study on safety and efficacy of sodium chlorophyllin in radiation induced cystitis
- Managed 13+ ongoing PK/PD studies across various cancers
- Developed research protocols with EORTC quality of life group for 4 QOL and Patient Reported Outcomes projects
- Performed complete geriatric assessments and medication reviews for patients ≥60 years
- Conceptualized studies on glomerular filtration rate estimating equations and potentially inappropriate medications scales
- Evaluated pharmacokinetics of anti-tubercular and anticancer drugs in geriatric patients
- Managed Therapeutic Drug Monitoring services for multiple medications
- Led pharmacovigilance activities at the center
Contributing Team Member - Real World Evidence Generation at Bristol-Myers Squibb Pvt. Ltd (2020-09 – 2024-01)
Leading real-world evidence generation initiatives for BMS India across multiple therapeutic areas
- Set up IEG Steering and IEG Cross Functional Teams
- Designed Evidence gap identification and Evidence generation workshops with cross-functional teams
- Collaborated with BMS India, WW HEOR, and RWDA teams for first evidence generation plan for India
- Developed IEG Plan for Oncology & Hematology & Cardiovascular TAs
- Designed NIR submissions and study tactics for SCCHN, NSCLC, and Beta-thalassemia
- Evaluated vendors, feasibility, and budgets for studies
- Achieved 3/3 approved studies in HNC, NSCLC & HOCM with global funding for first time for India
- Member of Checkmate 887 Study Publication Team for Nivolumab in 2L NSCLC & RCC in India
- Supported design of Phase IV study for Deucravacitinib in Indian moderate to severe plaque psoriasis patients
- Study team member on Multicounty RWE Muscle Invasive Bladder Cancer DSP II Study with Canada, China, Germany & UK
- Study team member on Brain Volume loss in Multiple Sclerosis study with BMS UK & Imperial College London
